Status:
UNKNOWN
the Real World Study of Orelabrutinib in the Treatment of CLL/SLL
Lead Sponsor:
Shandong University
Conditions:
CLL/SLL
Eligibility:
All Genders
18+ years
Brief Summary
This is a Multicenter, Retrospective Real-world Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China
Detailed Description
Orelabrutinib is a novel BTK inhibitor with high selectivity and has been approved in China for relapsed/refractory CLL/SLL,, The purpose of this study is to describe the effectiveness and safety of o...
Eligibility Criteria
Inclusion
- Age ≥18 years old
- Patients with a definite diagnosis of CLL/SLL
- Prior or current use of orelabrutinib for ≥3 months
- At least one follow-up was recorded during orelabrutinib treatment
Exclusion
- Patients who received orelabrutinib in a prospective clinical trial
Key Trial Info
Start Date :
July 25 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 10 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05975164
Start Date
July 25 2023
End Date
July 10 2024
Last Update
August 3 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.